Sodium Bicarbonate 8.4% Injection: mEq Calculation, Dilution and Emergency Compatibility
Sodium bicarbonate 8.4% is a hypertonic IV solution. It contains 84 mg/mL sodium bicarbonate, equivalent to 1 mEq/mL of sodium and bicarbonate: a 10 m
Drugs
Regulatory approvals, medicine status, safety communications and evidence-based drug updates.
Calcium Gluconate 10% Injection: IV Dilution, Symptomatic Hypocalcaemia and Extravasation Prevention
Calcium gluconate injection 10% contains 100 mg/mL calcium gluconate, corresponding to about 9.3 mg/mL elemental calcium. The manufacturer label recom
Magnesium Sulfate Injection 50%: Dilution, Eclampsia, Torsades and Toxicity Precautions
Magnesium sulfate is used under defined protocols for eclampsia/severe pre-eclampsia, torsades de pointes and selected electrolyte indications. A labe
Noradrenaline (Norepinephrine) Injection: Vasopressor Preparation, Concentrations and Nursing Monitoring
Norepinephrine is a vasopressor for severe hypotension after assessment and appropriate resuscitation. A manufacturer-labelled ready-to-use product co
Adrenaline (Epinephrine) Injection: Emergency Preparation, Anaphylaxis and IV Infusion Safety
Anaphylaxis is treated with prompt intramuscular adrenaline into the mid-outer thigh; a labelled 1 mg/mL preparation is distinct from a resuscitation
WHO World AMR Awareness Week 2026: One Health, One Action and a Practical CHC Antibiotic Stewardship Plan
WHO confirms World AMR Awareness Week on 18–24 November 2026. Explore the One Health theme, antibiotic stewardship, IPC and a practical CHC action plan.
CDSCO Fludrocortisone–Hypokalaemia Safety Signal: Mechanism, Monitoring and Clinical Red Flags
CDSCO’s September 2026 fludrocortisone–hypokalaemia ADR notification explained: mineralocorticoid mechanism, potassium and BP monitoring, safety documentation.
CDSCO 27 October 2026 ONDLS Notice: Digital Supply-Chain Monitoring for High-Risk Pharmaceutical Solvents
CDSCO’s 27 October 2026 public notice lists ONDLS digital monitoring for high-risk solvent supply chains. What is verified, what remains unclear and quality-system actions.
WHO MedSafetyWeek 2026 (2–8 November): How to Recognize and Report Adverse Drug Reactions in India
WHO #MedSafetyWeek 2–8 November 2026: practical suspected ADR recognition, documentation, reporting through India’s PvPI, and patient safety.
CDSCO FatX Notice: Why Cosmetic Registration Does Not Authorize Fat-Dissolving Treatment Claims
CDSCO’s 26 October 2026 notice concerns misleading or false claims for FatX solution marketed under a cosmetic registration. What clinicians and consumers should verify before aesthetic procedures.